论文部分内容阅读
目的探讨TET2蛋白(ten-eleven translocation 2)在不同分子亚型乳腺癌组织中的表达特点及与乳腺癌各临床因素之间的关系。方法免疫组化检测155例乳腺癌中TET2、ER、PR、Ki67和HER2蛋白的表达水平,FISH技术检测HER2基因扩增情况,结合患者相关资料进行分析。结果 TET2蛋白在Luminal B(HER2+)型乳腺癌组织中的表达水平明显下调(P<0.001),在HER2阳性的乳腺癌组织中也发现TET2表达水平下调(P<0.001),并且TET2表达水平还受到肿瘤大小和淋巴结转移等因素影响(P<0.001)。结论 TET2蛋白在不同分子亚型乳腺癌组织中的表达差异有统计学意义,并且与乳腺癌多项临床特征有关,可能有助于判断乳腺癌的预后。
Objective To investigate the expression of TET2 protein (ten-eleven translocation 2) in different molecular subtypes of breast cancer and its relationship with clinical factors of breast cancer. Methods The expression of TET2, ER, PR, Ki67 and HER2 protein in 155 cases of breast cancer were detected by immunohistochemistry. The amplification of HER2 gene was detected by FISH and the related data were analyzed. Results The expression of TET2 protein in Luminal B (HER2 +) breast cancer was significantly down-regulated (P <0.001). The expression of TET2 was also found to be down-regulated in HER2 positive breast cancer (P <0.001) Affected by tumor size and lymph node metastasis (P <0.001). Conclusion The expression of TET2 protein in different molecular subtypes of breast cancer has statistical significance, which is related to many clinical features of breast cancer and may be helpful in judging the prognosis of breast cancer.